Table 1.
Demographic and clinical data of study subjects.
| All subjects (n = 163) | Healthy controls (n = 54) | Schizophrenia patients (n = 41) | Bipolar patients (n = 41) | OCD patients (n = 27) | |
|---|---|---|---|---|---|
| Age (years) | 36.9 ± 12.1 | 39.6 ± 12.3 | 28.4 ± 7.1 | 43.2 ± 12.2 | 35.1 ± 9.8 |
| Gender (M/F) | 83/80 | 21/33 | 28/13 | 21/20 | 13/14 |
| Years of education | 13.6 ± 2.8 | 15.4 ± 2.7 | 12.7 ± 2.7 | 13.9 ± 2.9 | 12.7 ± 2.0 |
| Duration of illness in years | 0.7 ± 1.2 | 13.9 ± 10.6 | 13.7 ± 9.6 | ||
| MADRS | 12.3 ± 8.2 | 4.6 ± 3.5 | 9.7 ± 7.3 | ||
| CGI | 4.1 ± 0.9 | 3.4 ± 1.7 | 3.9 ± 1.2 | ||
| BDI | 14.5 ± 8.7 | 7.6 ± 10.4 | 13.0 ± 10.4 | ||
| PANSS | 88.9 ± 27.7 | ||||
| YMRS | 2.5 ± 2.8 | ||||
| Y-BOCS | 21.0 ± 9.1 | ||||
| CPZ dose equivalents | 320.5 ± 303.4 | 244.7 ± 425.3 |
M/F, male/female; MADRS, Montgomery–Asberg Depression Rating Scale; CGI, clinical global impression; BDI, Beck Depression Inventory; PANSS, Positive and Negative Syndrome Scale; YMRS, Young Mania Rating Scale; Y-BOCS, Yale–Brown Obsessive–Compulsive Scale; CPZ, chlorpromazine dose equivalent (daily), ±SD.